Ketosis-prone type 2 diabetes: Effect of hyperglycemia on β-cell function and skeletal muscle insulin signaling

Endocrine Practice

Volumn 13, Issue 3, 2007, Pages 283-290

  Umpierrez, Guillermo E ^a   Smiley, Dawn ^a   Gosmanov, Aidar ^b   Thomason, Donald ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIPID EMULSION;

AFRICAN AMERICAN; ARTICLE; CASE REPORT; DIABETIC KETOACIDOSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERGLYCEMIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

AFRICAN AMERICANS; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FAT EMULSIONS, INTRAVENOUS; FEMALE; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY;

EID: 34447571957     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.3.283     Document Type: Article

References (71)

1. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997;157:669-675.
2. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995;44:790-795.
3. Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53:645-653.
4. Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4: Flatbush diabetes. Diabetes. 1994;43:741-745.
5. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144:350-357.
6. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med. 2001;18:10-16.
7. Umpierrez GE, Clark WS, Steen MT. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. Diabetes Care. 1997;20:479-483.
8. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF. Diabetes in Africans. Part 2: Ketosis-prone atypical diabetes mellitus. Diabetes Metab. 2002;28:5-12.
9. Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003;88:5090-5098.
10. Wilson C, Krakoff J, Gohdes D. Ketoacidosis in Apache Indians with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:2098-2100.
11. Nagasaka S, Ishikawa S, Itabashi N, Rokkaku K, Saito T. Ketoacidosis-onset type 2 diabetes in Japanese: association with the widespread distribution of soft drinks and vending machines [letter]. Diabetes Care. 1998;21:1376-1378.
12. Aizawa T, Katakura M, Taguchi N, et al. Ketoacidosis-onset noninsulin dependent diabetes in Japanese subjects. Am J Med Sci. 1995;310:198-201.
13. Tan KC, Mackay IR, Zimmet PZ, Hawkins BR, Lam KS. Metabolic and immunologic features of Chinese patients with atypical diabetes mellitus. Diabetes Care. 2000;23:335-338.
14. Yan SH, Sheu WH, Song YM, Tseng LN. The occurrence of diabetic ketoacidosis in adults. Intern Med. 2000;39:10-14.
15. Hsin Yu E, Guo HR, Wu TJ. Factors associated with discontinuing insulin therapy after diabetic ketoacidosis in adult diabetic patients. Diabet Med. 2001;18:895-899.
16. Pinero-Pilona A, Litonjua P, Aviles-Santa L, Raskin P. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24:1014-1018.
17. Maldonado MR, Otiniano ME, Cheema F, Rodriguez L, Balasubramanyam A. Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. Diabet Med. 2005;22:1744-1750.
18. Umpierrez GE, Woo W, Hagopian WA, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care. 1999;22:1517-1523.
19. Banerji MA. Diabetes in African Americans: unique pathophysiologic features. Curr Diab Rep. 2004;4:219-223.
20. Kitabchi AE. Ketosis-prone diabetes - a new subgroup of patients with atypical type 1 and type 2 diabetes? J Clin Endocrinol Metab. 2003;88:5087-5089.
21. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar RP. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987;316:285-291.
22. Pinero-Pilona A, Raskin P. Idiopathic type 1 diabetes. J Diabetes Complications. 2001;15:328-335.
23. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001;24:131-153.
24. Osei K. Clinical evaluation of determinants of glycemic control: a new approach using serum glucose, C-peptide, and body mass indexes in type II diabetic patients. Arch Intern Med. 1986;146:281-285.
25. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
26. van Haeften TW, Voetberg GA, Gerich JE, van der Veen EA. Dose-response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia. J Clin Endocrinol Metab. 1989;69:1059-1064.
27. Levin SR, Karam JH, Hane S, Grodsky GM, Forsham PH. Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes. 1971;20:171-176.
28. Gosmanov AR, Schneider EG, Thomason DB. NKCC activity restores muscle water during hyperosmotic challenge independent of insulin, ERK, and p38 MAPK. Am J Physiol Regul Integr Comp Physiol. 2003;284:R655-R665.
29. Robertson RP. Type II diabetes, glucose "non-sense," and islet desensitization. Diabetes. 1989;38:1501-1505.
30. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 1994;43:1085-1089.
31. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
32. Davalli AM, Ricordi C, Socci C, et al. Abnormal sensitivity to glucose of human islets cultured in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. J Clin Endocrinol Metab. 1991;72:202-208.
33. Davalli AM, Pontiroli AE, Socci C, et al. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J Clin Endocrinol Metab. 1992;74:790-794.
34. Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest. 1983;71:1544-1553.
35. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234.
36. Gjessing HJ, Reinhold B, Pedersen O. The effect of chronic hyperglycaemia on the islet B-cell responsiveness in newly diagnosed type 2 diabetes. Diabet Med. 1992;9:601-604.
37. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
38. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia. 1991;34:891-898.
39. Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001;50(Suppl 1):S160-S163.
40. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415-431.
41. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985;28:119-121.
42. Giddings SJ, Chirgwin J, Permutt MA. Effects of glucose on proinsulin messenger RNA in rats in vivo. Diabetes. 1982;31:624-629.
43. Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr. Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol. 1992;262(4 Pt 1):E518-E523.
44. Byrne MM, Sturis J, Menzel S, et al. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes. 1996;45:1503-1510.
45. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74:1318-1328.
46. Ward WK, Halter JB, Beard JC, Porte D Jr. Adaptation of B and A cell function during prolonged glucose infusion in human subjects. Am J Physiol. 1984;246(5 Pt 1):E405-E411.
47. Halter JB, Graf RJ, Porte D Jr. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab. 1979;48:946-954.
48. Herman WH, Morrow LA, Halter JB. Maladaptation of beta-cell function to hyperglycemia in noninsulin-dependent diabetes mellitus (NIDDM) [abstract]. Diabetes. 1988;37(Suppl 1):17A.
49. Mason TM, Goh T, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes. 1999;48:524-530.
50. Balasubramanyam A, Zern JW, Hyman DJ, Pavlik V. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. Arch Intern Med. 1999;159:2317-2322.
51. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes. 1998;47:1613-1618.
52. Balasse EO, Ooms HA. Role of plasma free fatty acids in the control of insulin secretion in man. Diabetologia. 1973;9:145-151.
53. Crespin SR, Greenough WB III, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids: a direct pancreatic effect. J Clin Invest. 1973;52:1979-1984.
54. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001;50(Suppl 1):S118-S121.
55. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 1990;127:1580-1589.
56. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 1994;93:870-876.
57. Liang Y, Buettger C, Berner DK, Matschinsky FM. Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9). Diabetologia. 1997;40:1018-1027.
58. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol. 1999;276(6 Pt 1):E1055-E1066.
59. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes. 1995;44:1239-1242.
60. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes. 2000;49:399-408.
61. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem. 1998;182:153-160.
62. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999;103:931-943.
63. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-1515.
64. Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes. 1987;36:892-896.
65. Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss: effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest. 1992;89:701-705.
66. Tomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci. 2002;967:43-51.
67. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes. 1998;47:1281-1286.
68. Gosmanov AR, Umpierrez GE, Karabell AH, Cuervo R, Thomason DB. Impaired expression and insulin-stimulated phosphorylation of Akt-2 in muscle of obese patients with atypical diabetes. Am J Physiol Endocrinol Metab. 2004;287:E8-E15.
69. Kurowski TG, Lin Y, Luo Z, et al. Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle. Diabetes. 1999;48:658-663.
70. Oku A, Nawano M, Ueta K, et al. Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2001;280:E816-E824.
71. Rojas FA, Hirata AE, Saad MJ. Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes. Mol Cell Endocrinol. 2001;183:63-69.